<DOC>
	<DOCNO>NCT01345435</DOCNO>
	<brief_summary>A multi-center , randomize , parallel , interventional , open label trial compare Hemoglobin A1C-lowering effect conventional treatment Smart Care Service patient type 2 diabetes .</brief_summary>
	<brief_title>Effects Telemonitoring Telemedicine Service Type 2 Diabetes Care</brief_title>
	<detailed_description>1 . Objectives : To evaluate superiority Hemoglobin A1C -lowering effect Smart Care Service compare conventional treatment patient type 2 diabetes . 2 . Test control group - Control group : The subject group receive conventional treatment ( hospital visit ) . - Test group - Conventional treatment + remote monitor group : The subject group receive health care service use conventional treatment ( hospital visit ) remote monitor . - Remote visit + remote monitor group : The subject group receive remote visit remote monitor use videotelephony 3 . Target Subject : Type II diabetes patient</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . More 20 year age 60 year age 2 . Patients able receive outpatient treatment type II diabetes mellitus . 3 . If patient require use insulin , patient use basal insulin premixed insulin le 2 time day eligible . 4 . Patients HbA1c 7 % le 11 % ( 7 % ≤HbA1c≤11 % ) . 5 . Patients able understand purpose trial read write . 6 . Patients able use Smart Care PC study . 7 . Patients wired/wireless internet access home . 8 . Patients participate voluntarily sign informed consent . 1 . Patients type I diabetes mellitus 2 . Patients use Bolus insulin ( shortacting insulin ) insulin pump . 3 . Patients take medicine significantly affect glycemic control . 4 . Patients acute illness , untreated disease diabetic complication require additional treatment . 5 . Patients currently hospitalize planning hospitalize study period . 6 . Patients severe renal disease ( 1.5 time upper limit normal serum creatinine level ) . 7 . Pregnant lactating woman . 8 . Patients severe liver disease include cirrhosis ( AST ALT : 3 time upper limit normal ) . 9 . Patients uncontrolled chronic lung disease . 10 . Patients known history alcoholism , mental illness , drug dependency . 11 . Patients cognitive disorder psychiatric problem 12 . Patients participate clinical trial within 12 week prior screen visit . 13 . Any clinically significant medical condition include neurologic disease , gastrointestinal disease malignant tumor , etc. , may affect test result , medical condition opinion investigator make patient unsuitable participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>telemonitoring</keyword>
	<keyword>usual care</keyword>
	<keyword>telemedicine</keyword>
	<keyword>telehealth</keyword>
	<keyword>home care</keyword>
	<keyword>Health Care Quality</keyword>
	<keyword>Access</keyword>
	<keyword>Evaluation</keyword>
</DOC>